Distribution partnering Terms & Agreements in Pharma, Biotech & Diagnostics, 3rd Edition

The Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics reportprovides comprehensive understanding and unprecedented access to the distribution partnering agreementsentered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter distribution deals.The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultantproduct of the research collaboration. There are also numerous pure distribution deals whereby the productsoriginator takes on a distribution partner in order to maximize a products presence in the marketplace. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into thenegotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst manysmaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of howpayments are triggered - contract documents provide this insight where press releases and databases donot. This report contains over 500 links to online copies of actual distribution contract documents as submitted tothe Securities Exchange Commission by biopharma companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on awide range of important issues, many of which will have a significant impact on each party’s ability to derivevalue from the deal. The initial chapters of this report provide an orientation of distribution dealmaking and business activities.Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends indistribution as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of distribution deals. The chapter includes numerous casestudies to enable understanding of both pure distribution deals and multicomponent deals where distributionforms a part. Chapter 4 provides a review of the leading distribution deals since 2000. Deals are listed by headline value,signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the dealhas an agreement contract published at the SEC a link provides online access to the contract. Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summaryfollowed by a comprehensive listing of distribution contract documents available in the public domain. Eachdeal title links via Weblink to an online version of the actual contract document, providing easy access toeach contract document on demand. Chapter 6 provides a comprehensive listing of all distribution agreement contracts available in the publicdomain. Each chapter is organized by A-Z, stage of development at signing, and therapeutic area. Each dealtitle links via Weblink to an online version of the actual contract document, providing easy access to eachcontract document on demand. The report also includes numerous table and figures that illustrate the trends and activities in distributiondealmaking since 2000. In conclusion, this report provides everything a prospective dealmaker needs to know about distribution asan opportunity to participate in the commercialization of either candidate compounds in development or products already on the market.

Additional Information

Report scope

Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:

• Trends in distribution dealmaking in the biopharma industry since 2000
• Analysis of distribution deal structure
• Case studies of real-life distribution deals
• Access to over 500 distribution contract documents
• The leading distribution deals by value since 2000
• Most active distribution dealmakers since 2000
• The leading distribution partnering resources

In Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Therapeutic area

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive access to available contract documents for over 500 distribution deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise distribution rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?